In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth

X Shen, RJ Parks, DC Montefiori, JL Kirchherr… - Journal of …, 2009 - Am Soc Microbiol
X Shen, RJ Parks, DC Montefiori, JL Kirchherr, BF Keele, JM Decker, WA Blattner, F Gao
Journal of virology, 2009Am Soc Microbiol
The broadly neutralizing human monoclonal antibodies (MAbs) 2F5 and 4E10, both
targeting the highly conserved human immunodeficiency virus type 1 (HIV-1) envelope
membrane proximal external region (MPER), are among the MAbs with the broadest
heterologous neutralizing activity and are of considerable interest for HIV-1 vaccine
development. We have identified serum antibodies from an HIV-infected subject that both
were broadly neutralizing and specifically targeted MPER epitopes that overlap the 2F5 …
Abstract
The broadly neutralizing human monoclonal antibodies (MAbs) 2F5 and 4E10, both targeting the highly conserved human immunodeficiency virus type 1 (HIV-1) envelope membrane proximal external region (MPER), are among the MAbs with the broadest heterologous neutralizing activity and are of considerable interest for HIV-1 vaccine development. We have identified serum antibodies from an HIV-infected subject that both were broadly neutralizing and specifically targeted MPER epitopes that overlap the 2F5 epitope. These MPER-specific antibodies were made 15 to 20 months following transmission and concomitantly with the development of autoantibodies. Our findings suggest that multiple events (i.e., genetic predisposition and HIV-1 immune dysregulation) may be required for induction of broadly reactive gp41 MPER antibodies in natural infection.
American Society for Microbiology